Novan to Report Full Year 2022 Financial Results on March 30, 2023
Novan, Inc. (Nasdaq: NOVN) announced that it will release its full year 2022 financial results on March 30, 2023, followed by a conference call at 8:30 a.m. ET.
Rhea-AI Summary
Novan, Inc. (Nasdaq: NOVN) announced that it will release its full year 2022 financial results on March 30, 2023, followed by a conference call at 8:30 a.m. ET. The call will be led by President and CEO Paula Brown Stafford, with other management members participating. Investors can join via phone or live audio webcast on Novan's website, which will remain archived for 90 days.
Novan, a medical dermatology company, focuses on innovative therapies for skin diseases, including an FDA filing for berdazimer gel for molluscum contagiosum. The company leverages its nitric oxide-based technology platform, NITRICIL™, to develop new treatments.
Positive
- Expected conference call to discuss full year 2022 financial results, potentially positive for investor sentiment.
- FDA acceptance of Novan's NDA for berdazimer gel indicates progress in product development.
Negative
- None.
Details
News Market Reaction – NOVN
The recorded move for NOVN in the trading session of this news was -7.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.
About Novan
Novan, Inc. is a medical dermatology company primarily focused on developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel,
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.